Healthpeak Properties raises 2026 EPS guidance but lowers Nareit FFO outlook
Healthpeak reported first-quarter 2026 diluted EPS of $0.28, up from $0.06 a year earlier, while diluted Nareit FFO fell to $0.42 per share from $0.45. The company raised its full-year 2026 diluted EPS guidance to $0.46 to $0.50 from $0.34 to $0.38 and lowered its Nareit FFO guidance to $1.68 to $1.72 from $1.70 to $1.74, while raising FFO as Adjusted guidance and reaffirming same-store NOI growth.
Key points
- Q1 2026 diluted EPS $0.28 vs. $0.06 in Q1 2025; diluted Nareit FFO $0.42 vs. $0.45; diluted FFO as Adjusted $0.45 vs. $0.46.
- 2026 diluted EPS guidance raised to $0.46 to $0.50 from $0.34 to $0.38.
- 2026 Nareit FFO guidance lowered to $1.68 to $1.72 from $1.70 to $1.74; FFO as Adjusted guidance raised to $1.71 to $1.75 from $1.70 to $1.74.
- Janus Living IPO in March 2026 generated approximately $880 million of net proceeds; Healthpeak owns 81.6% of Janus Living.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.